Who
David W. Nassif
CFO / CLO
Company insider
Files Form 4 as: CFO / CLO, Pharvaris; Interim CEO, CFO, Sio Gene Therapies; EVP and CFO, SteadyMed.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.2M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 17 Jun 2016
- Last trade
- 21 Sep 2026
- Last filed
- 23 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 23 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $219K6,000 at $36.47 | filing |
| 21 Sep 2026filed 23 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code G | —500 at $0.00 | filing |
| 21 Sep 2026filed 23 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $219K6,000 at $36.47 | filing |
| 21 Sep 2026filed 23 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code G | —500 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $303K10,000 at $30.31 | filing |
| 21 May 2026filed 26 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $303K10,000 at $30.31 | filing |
| 8 Feb 2022filed 10 Feb 2022 | Sio Gene Therapiesoption or derivative | SEC FORM 4 Code A | —546,500 at $0.00 | filing |
| 8 Dec 2021filed 9 Dec 2021 | Sio Gene Therapiesoption or derivative | SEC FORM 4 Code D | —17,534 at $0.00 | filing |
| 8 Dec 2021filed 9 Dec 2021 | Sio Gene Therapies | SEC FORM 4 Code A | —17,534 at $0.00 | filing |
| 8 Dec 2021filed 9 Dec 2021 | Sio Gene Therapies | SEC FORM 4 Code F | $8,9376,294 at $1.42 | filing |
| 15 Apr 2021filed 19 Apr 2021 | Sio Gene Therapiesoption or derivative | SEC FORM 4 Code A | —239,000 at $0.00 | filing |
| 22 Mar 2021filed 22 Mar 2021 | Sio Gene Therapies | SEC FORM 4 Code A | —15,060 at $0.00 | filing |
| 22 Mar 2021filed 22 Mar 2021 | Sio Gene Therapiesoption or derivative | SEC FORM 4 Code D | —15,060 at $0.00 | filing |
| 12 Jun 2020filed 15 Jun 2020 | Axovant Gene Therapiesoption or derivative | SEC FORM 4 Code D | —15,060 at $0.00 | filing |
| 11 Jun 2020filed 15 Jun 2020 | Axovant Gene Therapies | SEC FORM 4 Code A | —15,060 at $0.00 | filing |
| 11 Jun 2020filed 15 Jun 2020 | Axovant Gene Therapies | SEC FORM 4 Code F | $17K5,266 at $3.25 | filing |
| 15 Apr 2020filed 17 Apr 2020 | Axovant Gene Therapiesoption or derivative | SEC FORM 4 Code A | —78,900 at $0.00 | filing |
| 15 Apr 2020filed 17 Apr 2020 | Axovant Gene Therapiesoption or derivative | SEC FORM 4 Code A | —52,600 at $0.00 | filing |
| 21 Sep 2019filed 24 Sep 2019 | Axovant Gene Therapiesoption or derivative | SEC FORM 4 Code A | —30,120 at $0.00 | filing |
| 1 Jul 2019filed 2 Jul 2019 | Axovant Gene Therapiesoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.